Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy
Copyright © 2020 Mercer, Torres, Duay, Lovie, Simpson, von Köckritz-Blickwede, de la Fuente-Nunez, O'Neil and Angeles-Boza..
During the development of antimicrobial peptides (AMP) as potential therapeutics, antimicrobial susceptibility testing (AST) stands as an essential part of the process in identification and optimisation of candidate AMP. Standard methods for AST, developed almost 60 years ago for testing conventional antibiotics, are not necessarily fit for purpose when it comes to determining the susceptibility of microorganisms to AMP. Without careful consideration of the parameters comprising AST there is a risk of failing to identify novel antimicrobials at a time when antimicrobial resistance (AMR) is leading the planet toward a post-antibiotic era. More physiologically/clinically relevant AST will allow better determination of the preclinical activity of drug candidates and allow the identification of lead compounds. An important consideration is the efficacy of AMP in biological matrices replicating sites of infection, e.g., blood/plasma/serum, lung bronchiolar lavage fluid/sputum, urine, biofilms, etc., as this will likely be more predictive of clinical efficacy. Additionally, specific AST for different target microorganisms may help to better predict efficacy of AMP in specific infections. In this manuscript, we describe what we believe are the key considerations for AST of AMP and hope that this information can better guide the preclinical development of AMP toward becoming a new generation of urgently needed antimicrobials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Frontiers in cellular and infection microbiology - 10(2020) vom: 17., Seite 326 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mercer, Derry K [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.06.2021 Date Revised 11.11.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fcimb.2020.00326 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313093385 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313093385 | ||
| 003 | DE-627 | ||
| 005 | 20231225145828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fcimb.2020.00326 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313093385 | ||
| 035 | |a (NLM)32733816 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mercer, Derry K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.06.2021 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Mercer, Torres, Duay, Lovie, Simpson, von Köckritz-Blickwede, de la Fuente-Nunez, O'Neil and Angeles-Boza. | ||
| 520 | |a During the development of antimicrobial peptides (AMP) as potential therapeutics, antimicrobial susceptibility testing (AST) stands as an essential part of the process in identification and optimisation of candidate AMP. Standard methods for AST, developed almost 60 years ago for testing conventional antibiotics, are not necessarily fit for purpose when it comes to determining the susceptibility of microorganisms to AMP. Without careful consideration of the parameters comprising AST there is a risk of failing to identify novel antimicrobials at a time when antimicrobial resistance (AMR) is leading the planet toward a post-antibiotic era. More physiologically/clinically relevant AST will allow better determination of the preclinical activity of drug candidates and allow the identification of lead compounds. An important consideration is the efficacy of AMP in biological matrices replicating sites of infection, e.g., blood/plasma/serum, lung bronchiolar lavage fluid/sputum, urine, biofilms, etc., as this will likely be more predictive of clinical efficacy. Additionally, specific AST for different target microorganisms may help to better predict efficacy of AMP in specific infections. In this manuscript, we describe what we believe are the key considerations for AST of AMP and hope that this information can better guide the preclinical development of AMP toward becoming a new generation of urgently needed antimicrobials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a antibiotic | |
| 650 | 4 | |a antifungal | |
| 650 | 4 | |a antimicrobial peptide (AMP) | |
| 650 | 4 | |a antimicrobial susceptibility testing | |
| 650 | 4 | |a host defence peptide (HDP) | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 650 | 7 | |a Pore Forming Cytotoxic Proteins |2 NLM | |
| 700 | 1 | |a Torres, Marcelo D T |e verfasserin |4 aut | |
| 700 | 1 | |a Duay, Searle S |e verfasserin |4 aut | |
| 700 | 1 | |a Lovie, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Simpson, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a von Köckritz-Blickwede, Maren |e verfasserin |4 aut | |
| 700 | 1 | |a de la Fuente-Nunez, Cesar |e verfasserin |4 aut | |
| 700 | 1 | |a O'Neil, Deborah A |e verfasserin |4 aut | |
| 700 | 1 | |a Angeles-Boza, Alfredo M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in cellular and infection microbiology |d 2011 |g 10(2020) vom: 17., Seite 326 |w (DE-627)NLM220414289 |x 2235-2988 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g day:17 |g pages:326 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fcimb.2020.00326 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |b 17 |h 326 | ||